References
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359-86. https://doi.org/10.1002/ijc.29210
- National Cancer Institute. SEER Cancer Stat Facts :Female Breast Cancer. Available from https://seer.cancer.gov/statfacts/html/breast.html. Accessed May 2, 2019.
- Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2015, Ministry of Health and Welfare, 2017. Available from http://ncc.re.kr/cancerStatsList.ncc?searchKey=total&searchValue=&pageNum=1. Accessed May 2, 2019.
- Migliaccio I, Malorni L, Hart CD, Guarducci C, Di Leo A. Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. BMC Med 2015;13:46. https://doi.org/10.1186/s12916-015-0280-0
- Reinbolt RE, Mangini N, Hill JL, et al. Endocrine therapy in breast cancer: the neoadjuvant, adjuvant, and metastatic approach. Semin Oncol Nurs 2015;31(2):146-55. https://doi.org/10.1016/j.soncn.2015.02.002
- Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348(24):2431-42. https://doi.org/10.1056/NEJMra023246
- Ramos-Esquivel A, Hernandez-Steller H, Savard MF, Landaverde DU. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials. Breast Cancer 2018;25(4):479-88. https://doi.org/10.1007/s12282-018-0848-6
- Hadji P, Ziller M, Albert US, Kalder M. Assessment of fracture risk in women with breast cancer using current vs emerging guidelines. Br J Cancer 2010;102(4):645-50. https://doi.org/10.1038/sj.bjc.6605548
- O'Sullivan CC. Overcoming endocrine resistance in hormonereceptor positive advanced breast cancer-the emerging role of CDK4/6 inhibitors. Int J Cancer Clin Res 2015;2(4):029. https://doi.org/10.23937/2378-3419/2/4/1029
- Boyle F, Beith J, Burslem K, et al. Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm. Asia Pac J Clin Oncol 2018;14(Suppl 4):3.
- National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: Breast cancer Version3.2015. Available from http://www.consensocancermamario.com/guias/NCCN_2015.pdf. Accessed July 29, 2019.
- National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: Breast Cancer Version3.2019. Available from https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed December 2, 2019.
- Finn RS, Crown JP, Ettl J, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res 2016;18(1):67. https://doi.org/10.1186/s13058-016-0721-5
- Scottish Intercolle giate Guidelines Network (SIGN). Critical appraisal notes and checklists Methodology checklist2: randomised controlled trial. Available from https://www.sign.ac.uk/checklistsand-notes.html. Accessed August 15, 2018.
- Choi YY, Sohn HS, Shin HT. Clinical benefits of self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: a systematic review and meta-analysis. Korean J of Clin Pharm 2010;20(3):183-92.
- Ministry of Food and Drug Safety. Easy-to-understand cancer glossary. Available from http://www.nifds.go.kr/brd/m_90/view.do?seq=23801&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1. Accessed July 29, 2019.
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-47. https://doi.org/10.1016/j.ejca.2008.10.026
- National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Available from http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed August 15, 2018.
- Thill M, Schmidt M. Management of adverse events during cyclindependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol 2018;10:1-10.
- Wallace BC, Schmid CH, Lau J, Trikalinos TA. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol 2009;9:80. https://doi.org/10.1186/1471-2288-9-80
- Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2018;29(7):1541-7. https://doi.org/10.1093/annonc/mdy155
- Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018;19(7):904-15. https://doi.org/10.1016/S1470-2045(18)30292-4
- Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 2019;5:5. https://doi.org/10.1038/s41523-018-0097-z
- Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375(20):1925-36. https://doi.org/10.1056/NEJMoa1607303
- Baselga J, Segalla JG, Roche H, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012; 30(13):1484-91. https://doi.org/10.1200/JCO.2011.36.7771
- Keller AM, Mennel RG, Georgoulias VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004;22(19):3893-901. https://doi.org/10.1200/JCO.2004.08.157
- Yardley DA, Hart L, Favret A, et al. Efficacy and safety of ribociclib with letrozole in US patients enrolled in the MONALEESA-2 study. Clin Breast Cancer 2019;19(4):268-77. https://doi.org/10.1016/j.clbc.2019.02.007
- Mukai H, Shimizu C, Masuda N, et al. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. Int J Clin Oncol 2019;24(3):274-87. https://doi.org/10.1007/s10147-018-1353-9
- Masuda N, Nishimura R, Takahashi M, et al. Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. Cancer Sci 2018; 109(3):803-13. https://doi.org/10.1111/cas.13507